

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Guangzhou Innogen Pharmaceutical Group Co., Ltd.

廣州銀諾醫藥集團股份有限公司

(A joint stock company established in the People's Republic of China with limited liability)

(Stock Code: 2591)

**(1) RESIGNATION OF DIRECTORS; AND
(2) CHANGE IN COMPOSITION OF STRATEGY COMMITTEE**

RESIGNATION OF DIRECTORS

The board (the “**Board**”) of directors (the “**Directors**”) of Guangzhou Innogen Pharmaceutical Group Co., Ltd. (the “**Company**”) hereby announces that:

- (i) Ms. Xu Wenjie (徐文潔) (“**Ms. Xu**”) has resigned as an executive Director, a member of the strategy committee of the Board (the “**Strategy Committee**”) and the vice president of the Company with effect from 16 October 2026 in order to devote more time to her personal commitments; and
- (ii) Mr. Heng Lei (衡磊) (“**Mr. Heng**”) has resigned as a non-executive Director with effect from 16 October 2026 in order to devote more time to his personal commitments.

Each of Ms. Xu and Mr. Heng has confirmed that he/she has no disagreement with the Board and there is no matter that needs to be brought to the attention of the shareholders of the Company (the “**Shareholders**”) and The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) in connection with his/her resignation. The Board is also not aware of other matters that need to be brought to the attention of the Shareholders and the Stock Exchange.

The Board would like to take this opportunity to express its gratitude to Ms. Xu and Mr. Heng for their contributions to the Company during their tenure of office.

CHANGE IN COMPOSITION OF STRATEGY COMMITTEE

Following the resignation of Ms. Xu as a member of the Strategy Committee, Mr. Huang Bing (黃冰) (“**Mr. Huang**”), an executive Director, has been appointed as a member of the Strategy Committee with effect from 16 October 2026.

The Board would like to extend a warm welcome to Mr. Huang on his new role in the Company.

By order of the Board
Guangzhou Innogen Pharmaceutical Group Co., Ltd.
Dr. WANG QINGHUA
Chairman of the Board

Shanghai, the People’s Republic of China, 16 October 2026

As at the date of this announcement, the Board comprises Dr. WANG QINGHUA, Ms. Jiang Fan and Mr. Huang Bing as executive Directors; Mr. HO KYUNG SHIK as non-executive Director; and Mr. Tao Wuping, Dr. Song Ruilin and Mr. Chan Heung Wing Anthony as independent non-executive Directors.